



CLOSE UP

A new approach to Life Science

Onelife is an advisory company combining Science and Finance since 2006

The Latin phrase “Prospere Senectute” or, in other words, prosperous senility is the vision of Enrico Braglia’s company Onelife. The idea was born in 2006, after he served as co-Ceo at the Swiss pharmaceutical company Helsinn for more than sixteen years, and then as an independent consultant focusing on the development of novel molecules and innovative drugs. Mr. Braglia invested his capital and energy to make a real contribution to the manifold

challenges in the Life Science sector. Onelife wants to pursue a new approach to Life Science and is becoming a recognized thought leader in the field of conjugating profitable and sustainable investments for its clients, investors and partners. Onelife is capitalizing on Mr. Braglia unique and holistic industry insight and expertise. “Onelife – he explains – aims to contribute to the healthcare sector, and to Life Science in particular.”

Onelife is working with compa-



THE COMPANY'S OFFICE

nies that provide solutions to the aging of the population and address unmet medical needs. Mr. Braglia stated, “I like to define Onelife as an interpreter between the scientific and financial communities. Often they do not speak each other’s language; however, Onelife is able to provide the missing link that allows these parties to successfully connect. Life Science is a complex sector requiring specific skills to navigate successfully. It is not just about analyzing data and coming up with answers. People’s future is the core of our activity and therefore a



MASSIMO COLNAGO AND ENRICO BRAGLIA



ENRICO BRAGLIA

unique know-how is paramount to operate in this sector”.

Onelife offers its clients both industrial expertise and a professional team (composed, in addition to Mr. Braglia, by Dr. Federica Pericle, the scientific expert, and by Massimo Colnago, the senior analyst). The team at Onelife addresses the growing and challenging needs of a market in rapid evolution. Overall, Onelife is committed to improving the quality of life of the aging population.

Onelife improves the value and manages complex bio-finance projects and data through refined methodologies for decision-making. The team advises Life Science companies, financial institutions, and high net worth Family Offices. With a

worldwide consultant network, the company is able to provide appropriate solutions to optimize pharmaceutical and biopharmaceutical projects and financial portfolios. “We also provide exclusive advisory services to investment funds in the pharmaceutical and biotechnology sectors. We focus on product analysis, market perspectives, therapeutic efficacy and commercial viability. This allows us to accurately determine the value of a company and the potential growth over the medium and long term.”

Onelife’s current projects include exclusive advisory to Prospera Senectute Fund, a life science fund investing in companies that address aging conditions. The fund has generated over 80% returns in an

eight-year track record. Exclusive advisory services are also provided to Bright Technologies Fund, which invests in privately held high-tech and innovative companies.

Finally, Mr. Braglia stated that he is most proud of Onelife’s commitment to social and ethical issues. “As per our bylaw, Onelife devotes 10% of company profits to charitable and public interest activities, such as the Swiss Alzheimer Society, the Rwanda Project (aids in access to clean drinking water) and Bench-to-Bed, a free advisory service to Life Science and high-tech start-ups”.



ONELIFE SA
LUGANO (SWITZERLAND)
www.onelife.ch

